IMPLICATIONS OF FLEROXACINS PHARMACOKINETIC PROFILE

被引:1
作者
NIGHTINGALE, CH
机构
[1] Hartford Hospital, Hartford, CT 06115
关键词
FLEROXACIN; PHARMACODYNAMICS; ELIMINATION; ABSORPTION; BODY DISTRIBUTION; DRUG INTERACTIONS;
D O I
10.1016/0924-8579(94)90016-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 h. Interactions with Ca2+ and Al3+ are minimal compared with other quinolones and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 h) allows once-a-day dosing. This may be of particular pharmacodynamic advantage when treating infections caused by organisms with relatively high MIC's. This feature, along with its modest drug interactions, indicates that fleroxacin will probably be an important quinolone useful in a variety of clinical settings.
引用
收藏
页码:S7 / S13
页数:7
相关论文
共 50 条
  • [31] Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation
    Kipourou, Maria
    Begou, Olga
    Manika, Katerina
    Ismailos, Georgios
    Kontou, Paschalina
    Pitsiou, Georgia
    Gika, Helen
    Kioumis, Ioannis
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [32] Effects of the dietary inclusion of a probiotic or prebiotic on florfenicol pharmacokinetic profile in broiler chicken
    Elgeddawy, Samy A.
    Shaheen, Hazem M.
    El-Sayed, Yasser S.
    Abd Elaziz, Magdy
    Darwish, Ashraf
    Samak, Dalia
    Batiha, Gaber E.
    Mady, Rehab A.
    Bin-Jumah, May
    Allam, Ahmed A.
    Alagawany, Mahmoud
    Taha, Ayman E.
    El-Mleeh, Amany
    El-Sayed, Sabry A. A.
    Abd El-Hack, Mohamed E.
    Elnesr, Shaaban S.
    JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION, 2020, 104 (02) : 549 - 557
  • [33] The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
    Teder, Kersti
    Maddison, Liivi
    Soeorg, Hiie
    Meos, Andres
    Karjagin, Juri
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [34] Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
    James, Angela Joubert
    Smith, Catherine C.
    Litzow, Mark
    Perl, Alexander E.
    Altman, Jessica K.
    Shepard, Dale
    Kadokura, Takeshi
    Souda, Kinya
    Patton, Melanie
    Lu, Zheng
    Liu, Chaofeng
    Moy, Selina
    Levis, Mark J.
    Bahceci, Erkut
    CLINICAL PHARMACOKINETICS, 2020, 59 (10) : 1273 - 1290
  • [35] Pharmacokinetic variation
    Eusuf, Danielle, V
    Thomas, Elizabeth
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2022, 23 (01) : 50 - 53
  • [36] Pharmacokinetic variation
    Eusuf, Danielle, V
    Thomas, Elizabeth
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2019, 20 (02) : 126 - 129
  • [37] Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications
    Tornio, Aleksi
    Niemi, Mikko
    Neuvonen, Pertti J.
    Backman, Janne T.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (06) : 312 - 322
  • [38] Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction
    Burkat, Paul M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (08) : 2569 - 2581
  • [39] Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD
    Swanson, JM
    Volkow, ND
    BEHAVIOURAL BRAIN RESEARCH, 2002, 130 (1-2) : 73 - 78
  • [40] Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis
    Rimmler, Christer
    Lanckohr, Christian
    Akamp, Ceren
    Horn, Dagmar
    Fobker, Manfred
    Wiebe, Karsten
    Redwan, Bassam
    Ellger, Bjoern
    Koeck, Robin
    Hempel, Georg
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (12) : 2864 - 2877